https://charts.traderzeitung.de/phases/US04683R1068 string(1400) "{"isin":"US04683R1068","name":"Atea Pharmaceuticals Inc","stock_id_xnas":16776084,"stock_id_xnys":null,"generated_at":"2026-09-24 01:32:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":5.42,"close_at":"2026-09-21 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":5.64,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":4.059},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":5.285,"close_at":"2026-09-23 21:59:00","complete":true,"perf_pct":-6.2943},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Atea Pharmaceuticals Aktie News & Nachrichten

[WKN: A2QGE7 | Symbol: AVIR]

Realtimekurs

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Atea Pharmaceuticals gefunden werden.

Atea Pharmaceuticals Nachrichtenticker öffnen

MT Newswires 13.08.2026 11:36 Uhr

Atea Pharmaceuticals Aktie News & Nachrichten

Artikel aus der Redaktion der Trader-Zeitung

Morgan Stanley passt Kursziel für Atea Pharmaceuticals von $6 auf $7 an, Rating bleibt Equalweight

Atea Pharmaceuticals gibt bekannt, dass Kombinationspräparat die Endpunkte in Phase-3-Studie zu Hepatitis C erreicht hat

Atea Pharmaceuticals beginnt klinische Phase-1-Studie für eine potenzielle Hepatitis-E-Behandlung

Atea Pharmaceuticals schließt Patientenrekrutierung in Phase-3-Studie zum Hepatitis-C-Virus außerhalb Nordamerikas ab